New Delhi: While Phase-1 human trials of Bharat Biotech’s Covaxin, India’s first indigenous COVID-19 vaccine candidate, are on at most of the 12 sites selected by Indian Council of Medical Research (ICMR) across the country, the Post-Graduate Institute of Medical Sciences (PGIMS), Rohtak, has claimed “encouraging” results from first part of tests.
Earlier this week, All India Institute of Medical Sciences (AIIMS), Delhi, administered the first dose of Covaxin to a 30-year-old man. According to Clinical Trials Registry - India (CTRI), the Covaxin Phase-1 and 2 trials are expected to take one year and three months.
